Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival-Reference-Cited by-同舟云学术

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

Published:2014-07-16 Issue:3 Volume:29 Page:689-695
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ferrero S,Ladetto M,Drandi D,Cavallo F,Genuardi E,Urbano M,Caltagirone S,Grasso M,Rossini F,Guglielmelli T,Cangialosi C,Liberati A M,Callea V,Carovita T,Crippa C,De Rosa L,Pisani F,Falcone A P,Pregno P,Oliva S,Terragna C,Musto P,Passera R,Boccadoro M,Palumbo A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014219.pdf

Reference24 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.

3. Chanan-Khan AA, Giralt S . Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612–2624.

4. Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017–4023.

5. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077–2084.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial;Bone Marrow Transplantation;2024-01-09

2. CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation;Aging;2022-11-28

3. Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?;Hemato;2022-06-23

4. Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT;Frontiers in Oncology;2022-05-18

5. Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma;British Journal of Haematology;2022-05-03